iRhythm Technologies第二季度业绩超预期，股价飙升13.4%

英为财情

2025/08/01

Investing.com -- iRhythm Technologies, Inc. (NASDAQ:IRTC)公布的第二季度财报显著超出分析师预期，推动公司股价上涨13.4%，投资者对公司强劲表现和上调全年指引反应积极。这家数字医疗公司第二季度调整后每股亏损为-$0.32，比分析师预估的-$0.51高出$0.19。营收增至1.867亿美元，同比增长26.1%，远超1.7398亿美元的市场共识...

网页链接

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券 | 轻松买卖美股港股A股/美债/ETF/Crypto/期权期货","description":"老虎证券提供多项优惠：港股&Crypto 0佣、A股通一年免佣、美股期权0佣、IPO打新0融资利息0手续费。 美股1美元起投，免费实时行情与多种工具，立即开户享更多优惠！","keywords":"老虎证券,老虎证券开户,老虎证券香港,老虎证券登录,老虎证券官网,香港证券开户,证券公司开户,股票开户,香港证券公司,香港证券,证券公司,股票投资,投资app,投资平台,股票买卖,股票交易平台,股票app,证券app,新手投资","social":{"ogDescription":"老虎证券提供多项优惠：港股&Crypto 0佣、A股通一年免佣、美股期权0佣、IPO打新0融资利息0手续费。 美股1美元起投，免费实时行情与多种工具，立即开户享更多优惠！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2556262854"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2556262854\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2556262854?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":false,"pubTime":"2025-08-01 07:04","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2556262854","market":"hk","top_or_hot":-1,"title":"iRhythm Technologies第二季度业绩超预期，股价飙升13.4%","media":"英为财情","content":"<div>\n<p>Investing.com -- iRhythm Technologies, Inc. (NASDAQ:IRTC)公布的第二季度财报显著超出分析师预期，推动公司股价上涨13.4%，投资者对公司强劲表现和上调全年指引反应积极。\n这家数字医疗公司第二季度调整后每股亏损为-$0.32，比分析师预估的-$0.51高出$0.19。营收增至1.867亿美元，同比增长26.1%，远超1.7398亿美元的市场共识...</p>\n\n<a href=\"https://cn.investing.com/news/earnings/article-93CH-2914323\">网页链接</a>\n\n</div>\n","source":"investing_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>iRhythm Technologies第二季度业绩超预期，股价飙升13.4%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\niRhythm Technologies第二季度业绩超预期，股价飙升13.4%\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-08-01 07:04 北京时间&nbsp;&nbsp;&nbsp;<a href=https://cn.investing.com/news/earnings/article-93CH-2914323><strong>英为财情</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Investing.com -- iRhythm Technologies, Inc. (NASDAQ:IRTC)公布的第二季度财报显著超出分析师预期，推动公司股价上涨13.4%，投资者对公司强劲表现和上调全年指引反应积极。\n这家数字医疗公司第二季度调整后每股亏损为-$0.32，比分析师预估的-$0.51高出$0.19。营收增至1.867亿美元，同比增长26.1%，远超1.7398亿美元的市场共识...</p>\n\n<a href=\"https://cn.investing.com/news/earnings/article-93CH-2914323\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4082","symbol_name":"医疗保健设备","start_time":0,"source_url":"https://cn.investing.com/news/earnings/article-93CH-2914323","article_id":"2556262854","we_media_id":null,"thumbnails":[],"rights":{"source":"investing_news","url":"https://cn.investing.com/news/earnings/article-93CH-2914323","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2556262854","pubTimestamp":1754003040,"columns":[],"sourceInfo":{"source_id":"investing_news","name":"英为财情新闻"},"weMediaInfo":null,"summary":"Investing.com -- iRhythm Technologies, Inc. 公布的第二季度财报显著超出分析师预期，推动公司股价上涨13.4%，投资者对公司强劲表现和上调全年指引反应积极。iRhythm上调了2025财年全年营收指引至7.2亿至7.3亿美元之间，大幅高于分析师共识的6.9575亿美元。这一改善主要归因于规模效应和运营效率提升，部分被Zio AT产品比例增加带来的成本上升所抵消。截至2025年6月30日，iRhythm报告的无限制现金、现金等价物和可交易证券达5.455亿美元。","collect":0,"end_time":0,"defaultTopTitle":"investing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK4082":"医疗保健设备","IRTC":"Irhythm Technologies Inc.","BK4563":"昨日强势股"},"translate_title":"iRhythm Technologies surges 13.4% after Q2 results beat expectations","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IRTC":1},"content_text":"Investing.com -- iRhythm Technologies, Inc. (NASDAQ:IRTC)公布的第二季度财报显著超出分析师预期，推动公司股价上涨13.4%，投资者对公司强劲表现和上调全年指引反应积极。\n这家数字医疗公司第二季度调整后每股亏损为-$0.32，比分析师预估的-$0.51高出$0.19。营收增至1.867亿美元，同比增长26.1%，远超1.7398亿美元的市场共识预期。\niRhythm上调了2025财年全年营收指引至7.2亿至7.3亿美元之间，大幅高于分析师共识的6.9575亿美元。公司还预计全年调整后EBITDA利润率将在营收的8.0%至8.5%之间。\n\"2025年第二季度是iRhythm又一个创纪录的季度，增长超过26%，展示了我们多元化增长战略的实力，\"iRhythm总裁兼首席执行官Quentin Blackford表示。\"我们持续的增长势头涵盖三个关键领域：核心监测业务加速增长、Zio AT在主要医疗系统中的持续渗透，以及与创新型价值导向医疗合作伙伴的成功拓展。\"\n公司毛利率提高至71.2%，比2024年第二季度上升了130个基点。这一改善主要归因于规模效应和运营效率提升，部分被Zio AT产品比例增加带来的成本上升所抵消。\n截至2025年6月30日，iRhythm报告的无限制现金、现金等价物和可交易证券达5.455亿美元。\n近期运营亮点包括与Lucem Health建立战略合作伙伴关系，以加速识别合并症患者中未确诊的心律失常，以及在美国糖尿病协会科学会议上展示的真实世界研究的有望结果。\n\n本文由人工智能协助翻译。更多信息，请参见我们的使用条款。","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}